Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PHIO PHARMACEUTICALS CORP.

(PHIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Phio Pharmaceuticals : HC Wainwright Adjusts Phio Pharmaceuticals' Price Target to $6 From $4, Keeps Buy Rating

06/14/2021 | 07:14am EDT


ę MT Newswires 2021
All news about PHIO PHARMACEUTICALS CORP.
07/07PHIO PHARMACEUTICALS : Scheduled to Participate in a Fireside Chat with H.C. Wai..
PR
06/22PHIO PHARMACEUTICALS : Reschedules Fireside Chat Hosted by H.C. Wainwright for J..
PR
06/21PHIO PHARMACEUTICALS CORP. : Submission of Matters to a Vote of Security Holders..
AQ
06/14PHIO PHARMACEUTICALS : Scheduled to Participate in Two Upcoming Investor Events ..
PR
06/14PHIO PHARMACEUTICALS : HC Wainwright Adjusts Phio Pharmaceuticals' Price Target ..
MT
06/07PHIO PHARMACEUTICALS : Presents new in vivo data at the 2021 asco annual meeting..
AQ
06/04PHIO PHARMACEUTICALS' : Study Shows Treatment With Intasyl May Induce Tumor Resp..
MT
06/04Phio Pharmaceuticals Presents New in Vivo Data At the 2021 Asco Annual Meetin..
CI
05/14PHIO PHARMACEUTICALS : Reports first quarter 2021 financial results and provides..
AQ
05/13PHIO PHARMACEUTICALS CORP. : Results of Operations and Financial Condition, Fina..
AQ
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -14,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,67x
Yield 2021 -
Capitalization 24,9 M 24,9 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 0,50x
Nbr of Employees 10
Free-Float 99,7%
Chart PHIO PHARMACEUTICALS CORP.
Duration : Period :
Phio Pharmaceuticals Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHIO PHARMACEUTICALS CORP.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,84 $
Average target price 6,00 $
Spread / Average Target 226%
EPS Revisions
Managers and Directors
Gerrit Dispersyn President, Chief Executive Officer & Director
Caitlin Kontulis Secretary, VP-Finance & Administration
Robert J. Bitterman Chairman
Simon Fricker Vice President-Research
James Cardia Vice President-Business Operations
Sector and Competitors
1st jan.Capi. (M$)
PHIO PHARMACEUTICALS CORP.-31.60%25
MODERNA, INC.234.37%131 902
LONZA GROUP AG20.01%55 520
IQVIA HOLDINGS INC.36.95%46 608
CELLTRION, INC.-27.16%31 131
SEAGEN INC.-16.58%26 209